Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. Abraham HD, Aldridge AM, Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology. 1996;14:285-298.
2. National Institute on Drug Abuse. Hallucinogens and Dissociative Drugs. Available at https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs. Last accessed September 23, 2024.
3. Dyck E. Flashback: psychiatric experimentation with LSD in historical perspective. Can J Psychiatry. 2005;50:381-388.
4. Halpern JH, Pope HG Jr. Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend. 1999;53:247-256.
5. Jacob P 3rd, Shulgin AT. Structure-activity relationships of the classic hallucinogens and their analogs. NIDA Res Monogr. 1994;146:74-91.
6. Khatchadourian R. High Anxiety: LSD in the Cold War. Available at https://www.newyorker.com/news/news-desk/high-anxiety-lsd-in-the-cold-war. Last accessed September 23, 2024.
7. Langlitz N. Neuropsychedelia: The Revival of Hallucinogen Research since the Decade of the Brain. 1st ed. Oakland, CA: University of California Press; 2012.
8. Monitoring the Future Study. National Survey Results on Drug Use, 1975-2022: Secondary School Students. Available at https://monitoringthefuture.org/wp-content/uploads/2022/12/mtf2022.pdf. Last accessed September 23, 2024.
9. Halpern JH, Suzuki J, Huertas PE, Passie T. Hallucinogen abuse and dependence. In: Encyclopedia of Psychopharmacology. Berlin: Springer Berlin Heidelberg; 2014: 1-5.
10. Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol. 2013;9(2):172-178.
11. Greene JP, Ahrendt D, Stafford EM. Adolescent abuse of other drugs. Adolesc Med Clin. 2006;17:283-318.
12. Stone AL, O'Brien MS, De La Torre A, Anthony JC. Who is becoming hallucinogen dependent soon after hallucinogen use starts? Drug Alcohol Depend. 2007;87:153-163.
13. Kovar KA. Chemistry and pharmacology of hallucinogens, entactogens and stimulants. Pharmacopsychiatry. 1998;31(Suppl 2): S69-S72.
14. Richardson WH 3rd, Slone CM, Michels JE. Herbal drugs of abuse: an emerging problem. Emerg Med Clin North Am. 2007;25:435-457.
15. Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacology. 1999;21(2 Suppl):16S-23S.
16. Giannini AJ. An approach to drug abuse, intoxication and withdrawal. Am Fam Physician. 2000;61:2763-2774.
17. Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamide. Addiction. 1993;88:1327-1334.
18. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14(4):295-314.
19. Halpern JH, Sewell RA. Hallucinogenic botanicals of America: a growing need for focused drug education and research. Life Sci. 2005;78:519-526.
20. Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002;7:357-64.
21. Garg A, Hippargi R, Gandhare A. Toad skin-secretions: potent source of pharmacologically and therapeutically significant compounds. Internet Journal of Pharmacology. 2007;5(2).
22. Shah AM, Calello DP, Quintero-Solivan J, Osterhoudt KC. The not-so-nice spice: a teenage girl with palpitations and dry mouth. Pediatr Emerg Care. 2011;27(12):1205-1207.
23. Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend. 2011;115(1-2):150-155.
24. Stříbrný J, Sokol M, Merová B, Ondra P. GC/MS determination of ibotenic acid and muscimol in the urine of patients intoxicated with Amanita pantherina. Int J Legal Med. 2012;126(4):519-524.
25. Nyberg H. Religious use of hallucinogenic fungi: a comparison between Siberian and Mesoamerican cultures. Karstenia. 1992;32:71-80.
26. Wasson RG. Soma: The Divine Mushroom of Immortality. New York, NY: Harcourt Brace Jovanovich, Inc.; 1972.
27. Allen TA, Narayanan NS, Kholodar-Smith DB, Zhao Y, Laubach M, Brown TH. Imaging the spread of reversible brain inactivations using fluorescent muscimol. J Neurosci Methods. 2008;171(1):30-38.
28. Michelot D, Melendez-Howell LM. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycol Res. 2003;107:131-146.
29. Escudié L, Francoz C, Vinel JP, et al. Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation. J Hepatol. 2007;46(3):466-473.
30. Satora L, Pach D, Ciszowski K, Winnik L. Panther cap Amanita pantherina poisoning case report and review. Toxicon. 2006;47:605-607.
31. Murray JB. Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. J Psychol. 2002;136:319-327.
32. Meyer MR, Maurer HH. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics. 2011;12(2):215-233.
33. Morris H, Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis. 2014;6(7-8):614-632.
34. Jacob MS, Carlen PL, Marshman JA, Sellers EM. Phencyclidine ingestion: drug abuse and psychosis. Int J Addict. 1981;16:749-758.
35. McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA. Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Em Med. 1981;10:237-242.
36. Marceaux JC, Dilks LS, Hixson S. Neuropsychological effects of formaldehyde use. J Psychoactive Drugs. 2008;40(2):207-210.
38. Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. 2004;26:127-131.
39. de Boer D, Bosman I. A new trend in drugs-of-abuse: the 2C-series of phenethylamine designer drugs. Pharm World Sci. 2004;26:110-113.
40. Kavanagh P, Dunne J, Feely J, et al. Phenylalkylamine abuse among opiate addicts attending a methadone treatment programme in the Republic of Ireland. Addict Biol. 2001;6:177-181.
41. United Nations Office on Drugs and Crime. 2014 Global Synthetic Drugs Assessment. Available at https://www.unodc.org/documents/scientific/2014_Global_Synthetic_Drugs_Assessment_web.pdf. Last accessed September 23, 2024.
42. Katagi M, Tsuchihashi H. Update on clandestine amphetamines and their analogues recently seen in Japan. J Health Sci. 2002;48:14-21.
43. Halpern JH, Pope HG Jr. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend. 2003;69:109-119.
44. Jensen S. A treatment program for alcoholics in a mental hospital. Q J Stud Alcohol. 1962;23:315-320.
45. Cohen S, Ditman KS. Complications associated with lysergic acid diethylamide (LSD-25). JAMA. 1962;181:161-162.
46. Sessa B. Is there a case for MDMA-assisted psychotherapy in the UK? J Psychopharmacol. 2007;21:220-224.
48. National Institute on Drug Abuse. NIDA Research Report: MDMA (Ecstasy) Abuse. Available at https://nida.nih.gov/sites/default/files/1763-mdma-ecstasy-abuse.pdf. Last accessed September 23, 2024.
49. Novak SJ. LSD before Leary: Sidney Cohen's critique of 1950s psychedelic drug research. Isis. 1997;88:87-110.
50. Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs. 1998;30(4):381-418.
51. U.S. Drug Enforcement Administration. Psilocybin. Available at https://www.dea.gov/factsheets/psilocybin. Last accessed September 23, 2024.
52. Radenkova J, Saeva E, Saev V. Psychoactive substances in different cultures and religious practices. Acta Medica Bulgarica. 2011;38(1):122-130.
53. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of {+/-}3,4-methylenedioxymetham-phetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011;25(4):439-452.
54. Substance Abuse and Mental Health Services Administration. Results from the 2023 National Survey on Drug Use and Health: Detailed Tables. Available at https://www.samhsa.gov/data/report/2023-nsduh-detailed-tables. Last accessed September 23, 2024.
55. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Detailed Tables. Available at http://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2013/NSDUH-DetTabs2013.htm. Last accessed September 23, 2024.
56. Burish MJ, Thoren KL, Madou M, Toossi S, Shah M. Hallucinogens causing seizures? A case report of the synthetic amphetamine 2,5-dimethoxy-4-chloroamphetamine. Neurohospitalist. 2015;5(1):32-34.
57. Baumeister D, Barnes G, Giaroli G, Tracy D. Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol. 2014;4(4):156-169.
58. Halberstadt AL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res. 2015;277:99-120.
59. Carbonaro T, Forster MJ, Gatch MB. The role of serotonin 2A and 2C receptors in tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine. Drug Alcohol Depend. 2014;140:e27.
60. Carhart-Harris R, Kaelen M, Nutt D. How do hallucinogens work on the brain? The Psychologist. 2014;27(9):662-665.
61. Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.J Psychopharmacol. 2012;26(7):994-1002.
62. Patel R, Titheradge D. MDMA for the treatment of mood disorder: all talk no substance? Ther Adv Psychopharmacol. 2015;5(3):179-188.
63. National Institutes of Health. MDMA (Ecstasy/Molly) Drug Facts. Available at https://www.drugabuse.gov/publications/drugfacts/mdma-ecstasymolly. Last accessed September 23, 2024.
64. Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol. 2015;5(2):97-132.
65. Wood DM, Sedefov R, Cunningham A, Dargan PI. Prevalence of use and acute toxicity associated with the use of NBOMe drugs.Clin Toxicol (Phila). 2015;53(2):85-92.
66. Oehen P, TRaver R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxy-methamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol. 2013;27(1):40-52.
67. Mithoefer MC, Mithoefer AT, Feduccia AA. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet. 2018;5(5):486-497.
68. United Nations Office on Drugs and Crime. 2020 Global Synthetic Drugs Assessment. Available at https://www.unodc.org/documents/scientific/Global_Synthetic_Drugs_Assessment_2020.pdf. Last accessed September 23, 2024.
70. Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol. 2015;172(17):4254-4276.
71. National Institutes of Health. Commonly Used Drugs Chart (GHB, Ketamine, Rohypnol). Available at https://nida.nih.gov/research-topics/commonly-used-drugs-charts. Last accessed September 23, 2024.
72. Reed JL, Nugent AC, Frey ML, et al. Ketamine normalizes brain activity during emotionally valenced attentional processing in depression. Neuroimage Clin. 2018;20:92-101.
73. Serafini G, Howland RH, Rovedi F, Girardi P, Amore M. The role of ketamine in treatment-resistant depression: a systematic review. Curr Neuropharmacol. 2014;12(5):444-461.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.